The financial trajectory of the exosome therapy market is decoupling from the broader, slower-growing regenerative medicine ...
The license agreement grants PranaX access to a core patent portfolio covering exosome manufacturing, engineering and therapeutic applications through a technology licensing agreement. This agreement ...
Exosome-associated THSD7A is identified as a key trigger of filopodia formation in cancer cells and neurons, revealing a ...
NEW ORLEANS, March 11, 2025 /PRNewswire/ -- A pioneering Phase 1 clinical trial, reported in a March 9, 2025, ScienceDaily article, is advancing stem cell therapies for Parkinson's disease. After over ...
cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields The disruptive, proprietary technology developed by EVerZom offers a ...
INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...
A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" of exosomes—tiny particles released from cancer cells in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results